Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

205.78 -1.54 (-0.74%)

Official Closing Price Updated: 4:10 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring? ↗

January 23, 2025

Via The Motley Fool

Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst ↗

January 23, 2025

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Via Benzinga

Where Johnson & Johnson Stands With Analysts ↗

January 23, 2025

Via Benzinga

This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Find ↗

January 23, 2025

Via The Motley Fool

Earnings Picture Remains Strong: A Closer Look ↗

January 22, 2025

Total earnings for the 62 S&P 500 companies that have reported results are up +19.6% from the same period last year on +8.4% higher revenues, with 82.3% beating EPS estimates and 69.4% beating revenue...

Via Talk Markets

Topics Stocks Stocks / Equities

S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run ↗

January 22, 2025

Market surges on AI Stargate initiative & strong earnings. S&P 500 hits record high of 6,100 points, led by tech giants & semiconductor stocks.

Via Benzinga

Topics Artificial Intelligence Government Stocks

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript ↗

January 22, 2025

JNJ earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Chipmakers Rally On AI Stargate Bet, Netflix Soars, Bitcoin Falters As Trump Keeps Quiet On Crypto: What's Driving Markets Wednesday? ↗

January 22, 2025

Tech stocks enjoyed a surge Wednesday, driven by a sharp rise in semiconductor shares after President Donald Trump, OpenAI's Sam Altman, Oracle Corp.

Via Benzinga

Topics Artificial Intelligence Government

Johnson & Johnson Q4 Earnings And Revenues Top Estimates ↗

January 22, 2025

Johnson & Johnson came out with quarterly earnings of $2.04 per share.

Via Talk Markets

Topics Stocks / Equities

J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilient ↗

January 22, 2025

During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually.

Via Stocktwits

Topics Earnings

Johnson & Johnson Tops Q4 EPS Forecasts ↗

January 22, 2025

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Via The Motley Fool

Topics Intellectual Property

Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook ↗

January 22, 2025

Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts.

Via Benzinga

Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light ↗

January 22, 2025

The Dow Jones stock fell slightly early Wednesday.

Via Investor's Business Daily

Topics Stocks

Johnson & Johnson Reports Q4 and Full-Year 2024 Results

January 22, 2025

From Johnson & Johnson

Via Business Wire

US Stocks Likely To Open Higher As President Trump Announces $500 Billion AI Project: Oracle, Netflix, Nvidia Among Top Stocks To Watch ↗

January 22, 2025

U.S. stocks could open on a positive note on Wednesday, continuing to rally after Donald Trump's inauguration as the 47th President of the U.S. on Monday.

Via Benzinga

Topics Artificial Intelligence Government

Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone ↗

January 22, 2025

The CNN Business Fear & Greed Index measures market sentiment, with higher fear putting pressure on stocks.

Via Benzinga

Topics Government Stocks

Earnings Scheduled For January 22, 2025 ↗

January 22, 2025

Via Benzinga

Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday ↗

January 22, 2025

Via Benzinga

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

January 22, 2025

Via Benzinga

Big Trading Day Ends With Q4 Earnings Beats: NFLX, UAL, COF ↗

January 21, 2025

Markets had a strong session on the first full day of President Trump’s second administration. Indexes have rocketed up from 2025 lows hit a week to a week and a half ago.

Via Talk Markets

Topics Government Stocks / Equities

Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse? ↗

January 21, 2025

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside

Via Benzinga

Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'? ↗

January 21, 2025

Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the key items and numbers to watch.

Via Benzinga

Topics Stocks

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression ↗

January 21, 2025

FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)

January 21, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. ↗

January 21, 2025

Via The Motley Fool

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗

January 21, 2025

Via The Motley Fool

Topics Stocks

3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever ↗

January 21, 2025

Via The Motley Fool

Healthcare And Biotech Stocks Lag The Market Again ↗

January 20, 2025

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Via Talk Markets

Topics Stocks / Equities

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

All News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today